

0360



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Takahashi, et al.

Examiner: NYA

Serial No.: 09/811,367

Group Art Unit: 1645

Filed: March 16, 2001

Docket: 021286/027 8719

For: **SOLUBLE MAST CELL FUNCTION ASSOCIATED ANTIGEN (MAFA)  
PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND  
USING THEM**

---

TRANSMITTAL LETTER

U.S. Patent and Trademark Office  
Box Sequence Listing, P.O. 2327  
Arlington, VA 22202

Transmitted herewith in the above-identified application are the following documents:


1. Response to Notice to Comply;
2. Copy of to Notice to Comply;
3. Sequence Listing in computer readable format and paper copy;
4. Statement Under 37 CFR § 1.821(f);and
5. Return Postcard.

---

**CERTIFICATE OF MAILING Under 37 C.F.R. § 1.8**

I hereby certify under 37 C.F.R. § 1.8 that this Response and corresponding transmittal documents are being deposited with the United States Postal Service to Addressee with sufficient postage on the date indicated below and is addressed to U.S. Patent and Trademark Office, Box Sequence Listing, P.O. 2327, Arlington, VA 22202

Dated: 3/7/02



Signature

---

SUZANNE L. SIMPSON

If the fee authorized is incorrect or if any other fees are due in connection with this submission, please charge any such fee or credit any overpayment to Deposit Account No. 03-3975.

Respectfully submitted,

Pillsbury Winthrop LLP

By: Alia T. DeJouy

PILLSBURY WINTHROP LLP  
50 Fremont Street  
San Francisco, CA 94105  
(858) 509-4065 Direct Dial  
(415) 983-1200 Facsimile



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Takahashi, et al.

Examiner: NYA

Serial No.: 09/811,367

Group Art Unit: 1645

Filed: March 16, 2001

Docket: 021286/027 8719

For: **SOLUBLE MAST CELL FUNCTION ASSOCIATED ANTIGEN (MAFA)  
PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND  
USING THEM**

---

**RESPONSE TO NOTICE TO COMPLY**

U.S. Patent and Trademark Office  
Box Sequence Listing, P.O. 2327  
Arlington, VA 22202

Sir:


Responsive to the communication mailed January 7, 2002, Applicants submit herewith a paper copy and a computer readable form (diskette) of the sequence listing as required under 37 C.F.R. §1.824 (a). The sequence listing is provided in MS-DOS Text with Line Breaks format on the accompanying diskette. A copy of the notice to comply is attached to this response.

The paper copy and computer readable forms of the sequence listing are identical and do not add new matter. A statement under 37 C.F.R. §1.821 (f) and (g) to that effect is provided. Accordingly, please amend the specification by entering the enclosed sequence listing.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 3-7-02

  
\_\_\_\_\_  
Robert M. Bedgood  
Reg. No. 43,488



UNITED STATES PATENT AND TRADEMARK OFFICE

S I P E  
M A R 1 2 2002  
P A T E N T & T R A D E M A R K O F F I C E

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/811,367	03/16/2001	Nobuaki Takahashi	021286/027 8719

CONFIRMATION NO. 6403

FORMALITIES LETTER



\*OC000000007270445\*

Robert M. Bedgood  
5th Floor  
50 Fremont Street  
San Francisco, CA 94105-2230

Date Mailed: 01/07/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

*Nolan*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART I - ATTORNEY/APPLICANT COPY